MP
ASLN

Mangrove Partners’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Mangrove Partners’s Portfolio ASLN Stock Details ASLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48,562
Closed -$1.75M – 564
2022
Q1 		$1.75M Sell
48,562
-14,302
-23% -$532K 0.09% 328
2021
Q4 		$2.82M Hold
62,864
– – 0.17% 201
2021
Q3 		$4.48M Hold
62,864
– – 0.4% 72
2021
Q2 		$8.3M Buy
62,864
+8,412
+15% +$1.05M 0.85% 21
2021
Q1 		$7.3M Buy
+54,452
New +$6.9M 0.74% 26

Other funds holding ASLN

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mangrove Partners's ASLN Position: Q2 2022 in Review

Mangrove Partners sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q2 2022, closing a stake of 48,562 shares — an estimated $1.75M sold.

Mangrove Partners first reported a position in ASLN in Q1 2021 and held it in 5 quarters. The position peaked at $8.3M in Q2 2021. 27 funds tracked by Wall St. Rank hold ASLN as of Q2 2022.

  • Mangrove Partners reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q2 2022 after selling out during the quarter.
  • Mangrove Partners sold 48,562 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q2 2022, an estimated $1.75M.
  • Mangrove Partners first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q1 2021 and held it in 5 quarters.
  • Mangrove Partners's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $8.3M in Q2 2021.
  • 27 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q2 2022.

Based on Mangrove Partners's 13F filing for Q2 2022, filed 15 Aug 2022.